BG
RPRX icon

Bellevue Group’s Royalty Pharma RPRX Stock Holding History

Bellevue Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.84M Buy
38,296
+25,095
+190% +$1.1M 0.04% 81
2025
Q4 		$510K Buy
13,201
+240
+2% +$9.15K 0.01% 134
2025
Q3 		$457K Buy
+12,961
New +$469K 0.01% 115

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bellevue Group's RPRX Position: Q1 2026 in Review

Bellevue Group increased its Royalty Pharma (RPRX) stake by 190% in Q1 2026, buying an estimated $1.1M and bringing the position to 38,296 shares worth $1.84M. The position accounts for 0.04% of the portfolio, ranked #81.

Bellevue Group first reported a position in RPRX in Q3 2025 and has held it in 3 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Bellevue Group held 38,296 shares of Royalty Pharma worth $1.84M as of Q1 2026.
  • Bellevue Group bought 25,095 Royalty Pharma shares in Q1 2026, an estimated $1.1M.
  • Royalty Pharma made up 0.04% of Bellevue Group's portfolio in Q1 2026, its #81 holding.
  • Bellevue Group first reported a position in Royalty Pharma in Q3 2025 and has held it in 3 quarters since.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.